… data from the GWTG-HF Registry, a national registry of patients hospitalized for HF from 2005
to … We identified patients with HF with ejection fractions ≤40% who were discharged alive …

… patients prescribed versus not prescribed sacubitril/valsartan, … therapy at discharge among
sacubitril/valsartan patients (ie, … used patient‐level clinical data from the GWTG‐HF registry, …

… 2.3% of patients discharged alive from hospitals in the large GWTG-HF registry were prescribed
… the study population included only patients discharged after acute HF hospitalization. …

… It is important to note that sacubitril/valsartan is currently approved and recommended for …
HFrEF patients only, and our GWTG-HF analysis includes postacute patients with HF at …

… patients regularly attending a community HF Clinic, who are still symptomatic, with stable,
moderate HFrEF, 38.4% of them could be eligible for sacubitril/valsartan … for worsening HF, …

… -world HF population. Methods: We included patients discharged alive from hospitals in
GWTG-HF between … We compared patient and hospital characteristics among HFrEF (EF≤40%) …

… in identifying the appropriate sacubitril/valsartan patient population in clinical practice for
fear of causing worsening symptoms in both stable and unstable patients. They may also be …

… Profile of sacubitril/valsartan in HF and patient selection … the profile of sacubitril/valsartan
in HF with regards to patient … Citation46 The GWTG-HF registry is composed of patients who …

… Importantly, sacubitril/valsartan is currently approved and recommended for chronic,
ambulatory HFrEF patients only, and our GWTG-HF analysis includes post-acute HF patients at …

… postpone >180 000 worsening HF events. Despite these potential … sacubitril/valsartan
among patients with HFmrEF and HFpEF. Similar delays in implementation of sacubitril/valsartan …